Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗

Topics Earnings

February 24, 2026

Via Chartmill

Why Did IOVA Stock Gain Pre-Market Today? ↗

February 24, 2026

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Via Stocktwits

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

February 24, 2026

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Why Are IOVA Shares Rising Today? ↗

November 06, 2025

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

February 24, 2026

The company is studying its approved drug for many other indications.

1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗

February 23, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

February 20, 2026

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

February 11, 2026

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

February 05, 2026

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

IOVA Shares Jump 8% — What’s Retail Expecting? ↗

January 26, 2026

Via Stocktwits

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

January 16, 2026

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗

December 29, 2025

Don't get too excited about their prospects.

Topics Death

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 19, 2025

This juicy upside potential comes at a cost.

2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗

December 07, 2025

Iovance (IOVA) Q3 2025 Earnings Call Transcript

Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Topics Earnings

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

November 21, 2025

Iovance has a long way to go to get to a break-even point, but the company has been showing progress.

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗

November 11, 2025

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗

November 07, 2025

Wall Street may be overestimating these companies' potential.

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Top movers in Thursday's session ↗

November 06, 2025

Via Chartmill

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026

November 06, 2025

Via AB Newswire

Top stock movements in today's session. ↗

November 06, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

Gapping stocks in Thursday's session ↗

November 06, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

November 06, 2025